All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice

Berenguer, Juan; Gil‐Martin, Ángela; Jarrín, Inmaculada; Moreno, Ana; Domínguez, Lourdes; Montes, Marisa; Aldámiz‐Echevarría, Teresa; Jesús Téllez, María; de los Santos, Ignacio; Benítez, Laura; Sanz, José; Ryan, Pablo; Gaspar, G.; Álvarez, Beatriz; Emilio Losa, Juan; Torres‐Perea, Rafael; Barrós, Carlos; V. San Martin, Juan; Arponen, Sari; Teresa de Guzmán, María; Monsalvo, Raquel; María Vegas, Ana; T. Garcia‐Benayas, María; Serrano, Regino; Gotuzzo, Luis; Antonia Menendez, María; M Belda, Luis; Malmierca, Eduardo; Clara Costa Calvo, Maria; Cruz‐Martos, Encarnación; González‐García, Juan

doi:10.1002/hep.29814

Public

All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice

Published in Hepatology • Jan 29, 2018

Authors:

Juan Berenguer

Ángela Gil‐Martin

Inmaculada Jarrín

Abstract

We evaluated treatment outcomes in a prospective registry of human immunodeficiency virus/hepatitis C virus (HCV)–coinfected patients treated with interferon‐free direct‐acting antiviral agent–based therapy in hospitals from the region of Madrid between November 2014 and August 2016. We assessed sus...

Subject

Ombitasvir

Dasabuvir

Paritaprevir

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!